Randomized controlled trial of 100 subjects, 71 completed 3 cycles of the ProLon® either in a randomized phase (N=39) or after being crossed over from a control diet group to the FMD group (N=32). Control subjects continued their normal diet. ProLon® participants consumed the fasting mimicking diet (FMD) for 5 consecutive days per month for 3 months. Measurements were performed prior to the diet (Before) and during the recovery period after the 3rd cycle (After).
IGF-1, marker associated with increased mortality and DNA damage in human cells, was reduced by 14%.
C-reactive protein (CRP) levels decreased from 1.5 mg/L to 1.0 mg/L after participants had resumed their normal diet for 5-8 days after cycle 3.
A transient, major, and significant elevation of stem cell/regenerative markers was also observed.
Participants lost an average of 5 lbs.
The weight loss came mostly from abdominal fat shown as reduction in abdominal fat mass.
> 1-inch loss in waist circumference.
Lean body mass was preserved.
Blood pressure (BP) was significantly reduced from 117.4 to 113.6 mm Hg (systolic).
And 75.7 to 72.8 mm Hg (diastolic).
Total cholesterol was reduced nearly 10 mg/dl with significant reductions of LDL from 104.9 to 99.2 mg/dl.
Prolon and Elevated Risk Cohorts
In obese participants (BMl>30), body weight decreased 9 lbs.
Weight remained significantly lower after subjects returned to their normal diet for an average of 3 months. In overweight participants (BMl>25), abdominal fat was reduced by >7%.
With preserved relative lean body mass and decreased waist circumference by approximately >3 cm.
In participants with high cholesterol (>199 mg/dl), total cholesterol was reduced by 20 mg/dl and LD-cholesterol reduced by 15 mg/dl.
In participants with high triglycerides (>100 mg/dl), triglyceride levels were reduced by >25 mg/dl.
For participants with high blood pressure (>120/80) systolic and diastolic BPs were reduced by >6 mmHg.
lGF-1, was reduced by 20% in participants with high lGF-1 levels.
In participants at an average risk for developing cardiovascular disease (C-reactive protein between 1-3 mg/L), CRP was lowered >1 mg/L closer to the lowest risk range.
How to Provide ProLon to Your Patients
Any licensed Health Care Provider (HCP) such as medical doctor, doctor of osteopathy, podiatrist, dentist, chiropractor, clinical psychologist, optometrist, nurse practitioner, nurse-midwife, or a clinical social worker can register with ProLon and then approve their patients or consumers to purchase ProLon.
THE PROCESS IS AS EASY AS 1 2 3
1. Register here and you will receive an email with your HCP code
2. Use your HCP code to buy ProLon for your clinic at the HCP discounted price and then provide it at your clinic to your patients for the retail price; and or
3. Provide your HCP code directly to your patient as a token of approval to buy ProLon. Then your patient would register on our website and use the Buy button to buy ProLon. All ProLon boxes are mailed for free by L-Nutra, whether to your clinic or your patient.
How Often Should Your Patients Take The 5-Day ProLon® Diet?
Depending on patients’ body weight, baseline markers and health measurements, and after the evaluation and recommendation of their health care provider:
Optimize Metabolic Health
3 consecutive cycles of ProLon (one per month) followed by ProLon every 2-3 months
Optimize General Health and Wellness
3-4 times a year
If you think that ProLon® may be right for you, contact your health care provider who can recommend and authorize the use of ProLon®; or contact us and we will get in touch with your health care provider or help find one near you.
Who Should Not Use ProLon®
Children under the age of 18
Women who are pregnant or nursing
Individuals who are allergic to nuts or soy
Individuals with a Body Mass Index (BMI) <18
Individuals diagnosed with serious medical condition or disease, unless approved in writing by a physician appropriately trained to treat that condition
Individuals who have been severely weakened by a disease or medical procedure
Individuals who are taking medications which may not be safely consumed with a calorie restricted diet unless authorized in writing by a licensed physician
Individuals with Diabetes (type 1 and type 2), cardiovascular disease and cancer, unless approved in writing by a licensed physician. ProLon® should never be combined with glucose lowering drugs, such as metformin or insulin
Fasting is prohibited for individuals with particular metabolic diseases, such as those affecting gluconeogenesis.
Individuals with a history of significant cardiac disease, particularly uncompensated congestive heart failure NYHA grade 2 or more or LVEF <40% on any prior assessment
Individuals with a history of syncope (fainting) with calorie restriction or other medical co-morbidities
Individuals who have special dietary needs that are incompatible with the ProLon® meal plan
Individuals with liver or kidney disorders that may be affected by the very low glucose and protein content of the diet